High volume movers were down, down, down. Exelixis and United Therapeutics both took dips following clinical trials of new drugs. Court ruling hits cigarette firm Lorillard while a downgrade hurt Credicorp. Lone riser is video game publisher Majesco.

Credicorp (NYSE: BAP) fell more than 13% on Monday morning after analysts at Raymond James downgraded the financial services holding company from “outperform” to “underperform.” BAP was trading below $88 on 2 million shares, nearly three times normal volume.

United Therapeutics Corp. (NASDAQ: UTHR) fell 6% to around $59 on trading of more than three times normal volume. The pharmaceutical company, which specializes in pulmonary medications such as Tyvaso, announced mixed results for study of a drug for arterial hypertension.

Lorillard (NYSE: LO), the manufacturer of Newport cigarettes, fell 7% on almost twice its normal trading volume. Share price fell below $100 for the first time since April. A court ruled last week that the judiciary should have continued involvement in the tobacco industry. LO is expected to pay out a quarterly dividend of $1.30 on its common stock on Friday. Nearly 3 million shares were exchanged.

Majesco Entertainment (NASDAQ: COOL) rose 12% as the video game publisher behind such popular franchises as Cooking Mama is rebounding. Shares trading over $3, close to the six-year high it hit in April. SmarTrend highlighted COOL as the technology industry stock with the highest forward earnings yield, more than 10%.

Exelixis (NASDAQ: EXEL), the pharmaceutical company specializing in cancer treatments, fell almost 17% as almost 6 million shares were traded by midday. A report this morning found that clinical trials of the company’s new drug cabozantinib caused the death of six patients. Shares were trading around $9.

As of this writing, Anthony John Agnello did not own a position in any of the stocks named here. Follow him on Twitter at @ajohnagnello and become a fan of InvestorPlace on Facebook.